First participants dosed in Phase 3 trial (ENSEMBLE) evaluating safety and efficacy of Janssen’s COVID-19 vaccine candidate, JNJ-78436735, also known as Ad26.COV2.S
Press Release
NEW BRUNSWICK, N.J., September 28, 2020 – Johnson & Johnson (NYSE: JNJ) (the Company) recently announced the launch of its large-scale, pivotal, multi-country Phase 3 trial (ENSEMBLE) for its COVID-19 vaccine candidate, JNJ-78436735, being developed by its Janssen Pharmaceutical Companies. The initiation of the ENSEMBLE trial follows positive interim results from the Company’s Phase 1/2a clinical study, which demonstrated that the safety profile and immunogenicity after a single vaccination were supportive of further development.
In the context of the news this week, we find ourselves in another pivotal moment. Not only is it Climate Week, but the U.S. faced yet another racial injustice in Breonna Taylor’s court ruling. Today’s newsletter addresses these issues and how they, and so many other issues of today, intersect.
by Alex Gorsky Chairman of the Board and Chief Executive Officer, Johnson & Johnson
Blog
It’s hard to believe that just six months have passed since our scientists identified Janssen’s lead COVID-19 vaccine candidate. We couldn’t have predicted all the changes that have happened since. Two things, however, have been constant: COVID-19 continues to be a devastating pandemic, and Johnson & Johnson has been working around the clock on a potential solution.
In signing the pledge, we are joining eight other biopharmaceutical companies working on vaccine research and development in making the safety and well-being of vaccinated individuals our top priority.
Article
Recently, Johnson & Johnson announced that we, alongside eight other companies working on investigational COVID-19 vaccines, are signing a #WeStandWithScience pledge committed to upholding the integrity of the scientific process as we work towards potential global regulatory filings and approvals of the first vaccines for COVID-19.
In Season 2 of "The Road to a Vaccine," host Lisa Ling interviews scientists, global health leaders and other experts on the COVID-19 front lines to reveal the latest medical advances and collaborations to create a coronavirus vaccine—and hopefully a return to a world without the pandemic.
In Episode 5, Lisa Ling asks health experts for a pandemic status report, including the latest statistics on cases worldwide, the current thinking about coronavirus and its effects and what’s working to fight the disease—and what’s not.
From epidemic masks that the company introduced during the Spanish flu pandemic to work it's doing today on an investigational COVID-19 vaccine, learn how the company has been at the forefront of safeguarding global public health for well over a century.
Article
From epidemic masks that the company introduced during the Spanish flu pandemic to work it's doing today on an investigational COVID-19 vaccine, learn how the company has been at the forefront of safeguarding global public health for well over a century.
In this bonus clip from “The Road to a Vaccine,” health experts explain why communities of color in the U.S. are disproportionately affected by COVID-19—and how to help solve this glaring disparity.
Be sure to tune in for the next live episode, returning September 8 at 12 PM ET.
What will the laboratory of the future look like, especially when dealing with post-COVID realities?
Given the current situation of working during a pandemic, we really do need to be innovative in how we design labs today for use tomorrow.
What’s becoming clear is that robotics and automation will increasingly color the way we think about labs. For example, if a lab is pushed to increase from 5,000 to 100,000 COVID tests per day, one would be hard-pressed to solve the problem without some significant level of robotics and automation.
